NDA 204447 · Takeda Pharms USA
Trintellix
Vortioxetine Hydrobromide · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Sep 30, 2013
Approved uses
7
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
17,188
8,272 serious, 1,016 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . TRINTELLIX is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). TRINTELLIX is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Apr 23, 2026.
TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 , 14 ).
Mechanism: The mechanism of the antidepressant effect of vortioxetine is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to vortioxetine's antidepressant effect has not been established.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 23, 2023 Supplement 26 · Efficacy · priority review LetterLabelMedication Guide
- Jan 22, 2021 Supplement 21 · Efficacy · priority review LetterLabel
- Nov 13, 2020 Supplement 20 · Efficacy LetterLabelReview
- Oct 19, 2018 Supplement 17 · Efficacy LabelLetterReview
- May 2, 2018 Supplement 6 · Efficacy LetterLabel
- Mar 10, 2017 Supplement 9 · Efficacy LabelLetterReview
- Sep 30, 2013 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLabel
4 products under this application
- TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 10MG BASE · TABLET, ORAL · Prescription
- TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 5MG BASE · TABLET, ORAL · Prescription
- TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vortioxetine Hydrobromide" as an intervention, any sponsor and status, largest first.
- Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive DisorderPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07741331 · 326 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: KH607 tablets; Vortioxetine Hydrobromide Tablets and 1 more · For: Major Depressive Disorder (MDD)
- Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsCompleted
Seasons Biotechnology (Taizhou) Co., Ltd.Industry
NCT05417087 · 48 participants · Start Jun 27, 2022 · Primary completion Sep 2, 2022
Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets; Vortioxetine Hydrobromide Tablets · For: Major Depressive Disorder (MDD)
Sites: Ahmedabad, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,284
- fatigue1,225
- drug ineffective1,165
- headache1,075
- anxiety1,053
- vomiting1,036
- suicidal ideation969
- off label use948
- insomnia942
- dizziness904
- diarrhoea850
- pruritus806
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 10 |
| 2015 | 116 |
| 2016 | 1,444 |
| 2017 | 2,154 |
| 2018 | 1,866 |
| 2019 | 2,005 |
| 2020 | 1,668 |
| 2021 | 1,553 |
| 2022 | 1,419 |
| 2023 | 1,274 |
| 2024 | 1,442 |
| 2025 | 1,323 |
| 2026 | 913 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trintellix (Vortioxetine Hydrobromide)
2024 spending
$392M
Beneficiaries
100,706
610,008 claims
Per beneficiary
$3,897
$16.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $314,974,935 |
| 2021 | $337,760,606 |
| 2022 | $366,780,643 |
| 2023 | $389,714,302 |
| 2024 | $392,486,138 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Bai W, Song H, Hu Y, et al. · Drug Des Devel Ther 2023 · Equivalence Trial
- Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults.
Zhang X, Cai Y, Hu X, et al. · Front Psychiatry 2022 · Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.